M. Holick, Vitamin D Deficiency, New England Journal of Medicine, vol.357, issue.3, pp.266-281, 2007.
DOI : 10.1056/NEJMra070553

S. Christakos, M. Hewison, D. Gardner, C. Wagner, I. Sergeev et al., Vitamin D: beyond bone, Annals of the New York Academy of Sciences, vol.88, issue.7, pp.45-58, 2013.
DOI : 10.1111/nyas.12129

M. Kallas, F. Green, M. Hewison, C. White, and G. Kline, Rare Causes of Calcitriol-Mediated Hypercalcemia: A Case Report and Literature Review, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.7, pp.3111-3117, 2010.
DOI : 10.1210/jc.2009-2673

P. Malloy and D. Feldman, Genetic Disorders and Defects in Vitamin D Action, Endocrinology and Metabolism Clinics of North America, vol.39, issue.2, pp.333-346, 2010.
DOI : 10.1016/j.ecl.2010.02.004

B. Hollis, D. Johnson, and T. Hulsey, Vitamin D supplementation during pregnancy: Double-blind, randomized clinical trial of safety and effectiveness, Journal of Bone and Mineral Research, vol.73, issue.4535, pp.2341-2357, 2011.
DOI : 10.1002/jbmr.463

P. Patron, J. Gardin, and M. Paillard, Renal mass and reserve of vitamin D: Determinants in primary hyperparathyroidism, Kidney International, vol.31, issue.5, pp.1174-1180, 1987.
DOI : 10.1038/ki.1987.125

A. Dusso, A. Brown, E. Slatopolsky, and D. Vitamin, Vitamin D, AJP: Renal Physiology, vol.289, issue.1, pp.8-28, 2005.
DOI : 10.1152/ajprenal.00336.2004

B. Lund, O. Sorensen, J. Lund, J. Bishop, and A. Norman, Vitamin D Metabolism in Hypoparathyroidism, The Journal of Clinical Endocrinology & Metabolism, vol.51, issue.3, pp.606-610, 1980.
DOI : 10.1210/jcem-51-3-606

B. Hollis, J. Kamerud, A. Kurkowsky, J. Beaulieu, and J. Napoli, Quantification of circulating 1,25 dihydroxyvitamin D by radio-immunoassay with an 125 I-labeled tracer, Clin Chem, vol.45, pp.586-592, 1996.

W. Frazer, B. Durhan, J. Berry, and E. Mawer, Measurement of Plasma 1,25 Dihydroxyvitamin D Using a Novel Immunoextraction Technique and Immunoassay with Iodine Labelled Vitamin D Tracer, Annals of Clinical Biochemistry: An international journal of biochemistry and laboratory medicine, vol.34, issue.6, pp.632-637, 1997.
DOI : 10.1177/000456329703400606

B. Casetta, I. Jans, D. Billen, and R. Bouillon, Development of a method for the quantification of 1??,25(OH)2???vitamin D3 in serum by liquid chromatography tandem mass spectrometry without derivatization, European Journal of Mass Spectrometry, vol.16, issue.1, pp.81-89, 2010.
DOI : 10.1255/ejms.1024

F. Stratham, T. Laha, and A. Hoofnagle, Quantification of 1??,25-Dihydroxy Vitamin D by Immunoextraction and Liquid Chromatography-Tandem Mass Spectrometry, Clinical Chemistry, vol.57, issue.9, pp.1279-1285, 2011.
DOI : 10.1373/clinchem.2010.161174

J. Van-helden and R. Weiskirchen, Experience with the first fully automated chemiluminescence immunoassay for the quantification of 1a,25-dihydroxy-vitamin D, Clin Chem Lab Med, vol.53, pp.761-770, 2015.

E. Koumakis, J. Souberbielle, E. Sarfati, M. Meunier, E. Maury et al., Bone Mineral Density Evolution After Successful Parathyroidectomy in Patients With Normocalcemic Primary Hyperparathyroidism, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.8, pp.3213-3233, 2013.
DOI : 10.1210/jc.2013-1518

E. Cavalier, Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-ofconcept and safety study, Nephrol Dial Transplant, vol.28, pp.1779-1786, 2013.

P. Horn, L. Feng, Y. Li, and A. Pesce, Effect of outliers and non healthy individuals on reference interval estimation, Clin Chem, pp.2137-3145, 2001.

M. Davies, P. Adams, J. Berry, G. Lumb, P. Klimiuk et al., Familial hypocalciuric hypercalcemia-observation on vitamin D metabolism and parathyroid function

W. 19-law, S. Bollman, R. Kumar, H. Heath, and . Iii, Vitamin D Metabolism in Familial Benign Hypercalcemia (Hypocalciuric Hypercalcemia) Differs from That in Primary Hyperparathyroidism*, The Journal of Clinical Endocrinology & Metabolism, vol.58, issue.4, pp.744-747, 1984.
DOI : 10.1210/jcem-58-4-744

L. Mosekilde, Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism, Eur J Endocrinol, vol.159, pp.719-727, 2008.

B. Moosgard, S. Christensen, P. Vestergaard, L. Heickendorff, P. Christiansen et al., Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism, Clinical Endocrinology, vol.1, issue.2, pp.707-715, 2008.
DOI : 10.1210/jc.2004-1772

B. Lalor, E. Mawer, M. Davies, G. Lumb, L. Hunt et al., Determinants of the serum concentration of 1,25-dihydroxyvitamin D in primary hyperparathyroidism, Clinical Science, vol.76, issue.1, pp.81-86, 1989.
DOI : 10.1042/cs0760081

R. Thakker, L. Fraher, S. Adami, R. Karnali, O. Riordan et al., Circulating concentrations of 1,25-dihydroxyvitamin D3 in patients with primary hyperparathyroidism, Bone and Mineral, vol.1, pp.137-144, 1986.

A. Bergenfelz, B. Lindegard, and B. Ahren, Biochemical variables associated with bone density in patients with primary hyperparathyroidism, Eur J Surgery, vol.158, pp.473-476, 1992.

E. Nordenström, J. Westerdahl, and A. Bergenfelz, Recovery of bone mineral density in 126

R. Kumar, W. Cohen, P. Silva, and F. Epstein, Elevated 1,25-dihydroxyvitamin D plasma levels in normal human pregnancy and lactation., Journal of Clinical Investigation, vol.63, issue.2, pp.342-344, 1979.
DOI : 10.1172/JCI109308

G. Reddy, A. Norman, D. Willis, D. Goltzman, H. Guyda et al., Regulation of Vitamin D Metabolism in Normal Human Pregnancy*, The Journal of Clinical Endocrinology & Metabolism, vol.56, issue.2, pp.363-370, 1983.
DOI : 10.1210/jcem-56-2-363

L. Rejnmark, Changes in calciotropic hormones, bone markers and insulin-like growth factor I (IGF-I) during pregnancy and postpartum: a controlled cohort study, Osteoporos Int, vol.24, pp.1307-1320, 2013.

J. Whitsett, M. Ho, R. Tsang, E. Norman, and K. Adams, by Human Placenta in Vitro*, The Journal of Clinical Endocrinology & Metabolism, vol.53, issue.3, pp.484-488, 1981.
DOI : 10.1210/jcem-53-3-484

B. Halloran, P. Schaefer, M. Lifschitz, M. Levens, and R. Goldsmith, Plasma Vitamin D Metabolite Concentrations in Chronic Renal Failure: Effect of Oral Administration of 25-Hydroxyvitamin D3*, The Journal of Clinical Endocrinology & Metabolism, vol.59, issue.6, pp.1063-1069, 1984.
DOI : 10.1210/jcem-59-6-1063

G. Jean, J. Terrat, and T. Vanel, Evidence for Persistent Vitamin D 1-Alpha-Hydroxylation in Hemodialysis Patients: Evolution of Serum 1,25-Dihydroxycholecalciferol after 6 Months of 25-Hydroxycholecalciferol Treatment, Nephron Clinical Practice, vol.110, issue.1, pp.58-65, 2008.
DOI : 10.1159/000151534

G. Jean, J. Souberbielle, and C. Chazot, Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation, Nephrology Dialysis Transplantation, vol.24, issue.12
DOI : 10.1093/ndt/gfp370

G. Barbour, J. Coburn, E. Slatopolsky, A. Norman, and R. Horst, Hypercalcemia in an Anephric Patient with Sarcoidosis: Evidence for Extrarenal Generation of 1,25-Dihydroxyvitamin D, New England Journal of Medicine, vol.305, issue.8, pp.440-443, 1981.
DOI : 10.1056/NEJM198108203050807

A. Dusso, S. Lopez-hilker, N. Rapp, and E. Slatopolsky, Extra-renal production of calcitriol in chronic renal failure, Kidney International, vol.34, issue.3, pp.368-375, 1988.
DOI : 10.1038/ki.1988.190

P. Serum, 0) Serum calcium (mmol/L) 2.30 ± 010-2.60) Serum phosphate, pp.20-26